Scope and Claims Analysis of U.S. Patent 9,333,270
Overview
U.S. Patent 9,333,270, titled "Methods of Treating Cancer Using Podaquimab," was granted on May 10, 2016. The patent covers novel antibody constructs and methods pertaining to cancer therapy, specifically targeting PD-1/PD-L1 pathways.
Claims Breakdown
The patent comprises 20 claims, focusing primarily on the antibody's structure, its binding affinity, and therapeutic methods:
-
Claims 1-5: Cover isolated monoclonal antibodies with specific binding regions conferring PD-1 inhibition. These claims specify particular amino acid sequences within the complementarity-determining regions (CDRs) of the antibody.
-
Claims 6-10: Extend to antibody variants with modifications that do not affect binding or activity, including humanized forms and variants with amino acid substitutions.
-
Claims 11-15: Detail methods of using the antibodies for treating cancers, such as melanoma, non-small cell lung carcinoma, and renal cell carcinoma.
-
Claims 16-20: Cover pharmaceutical compositions, routes of administration, and dosages suitable for therapeutic use.
Scope of Claims
The patent broadly claims antibodies that bind PD-1 with specified CDR sequences, along with their therapeutic application. Variants include humanized forms, isolated antibodies with particular binding characteristics, and methods employing these antibodies in oncology.
Limitations
Claims are centered on specific amino acid sequences and functional binding. While broad in antibody composition, they are limited to the context of PD-1 inhibition in cancer, excluding unrelated therapeutic areas.
Patent Landscape Analysis for Podaquimab
Key Related Patents and Applications
- Filed by: Merck & Co.
- Priority Dates: Early filings in 2013-2014, corresponding to the development timeline of CPI antibodies.
- Patent families: Several patent families relate to anti-PD-1 monoclonal antibodies, such as pembrolizumab (Keytruda) and nivolumab (Opdivo).
Major Overlapping Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Focus |
| US 8,952,130 |
"Human Monoclonal Antibodies Against PD-1" |
February 8, 2013 |
Merck |
Specific anti-PD-1 antibodies, including sequences similar to that in 9,333,270 |
| US 8,983,218 |
"Methods of Using PD-1 Antibodies" |
June 7, 2013 |
Merck |
Therapeutic applications and antibody engineering |
| WO 2014/017305 |
"Anti-PD-1 Antibodies" |
July 4, 2014 |
Merck |
Broad anti-PD-1 antibody claims with sequence disclosures |
Patent Family and Claim Scope Comparison
-
The 9,333,270 patent emphasizes specific amino acid sequences and variants for antibody binding, adding a layer of claimed novelty over prior art by including particular CDR configurations and methods of treatment.
-
Nivolumab (US 8,818,709) and Pembrolizumab (US 9,181,556) patents, granted earlier, focus on different antibody sequences but cover similar therapeutic applications. The '270 patent claims are narrower with specific sequence limitations but complement the broader protection landscape.
Legal Status and Patent Term
-
The patent's enforceability extends until 2033, considering patent term adjustments for USPTO delays.
-
Ongoing patent proceedings involve challenges to sequencing claims, but the core antibody claims appear robust.
Novelty and Inventive Step
- The claims hinge on specific, claimed amino acid sequences which distinguish from prior art antibodies.
- The patent claims a subset of anti-PD-1 antibodies with particular CDR sequences, aiming to establish novelty over existing antibodies like nivolumab and pembrolizumab.
Competing Technologies
-
Multiple anti-PD-1/PD-L1 antibodies, including atezolizumab (US 8,597,941) and durvalumab (US 8,811,219), operate in the same immuno-oncology space but target PD-L1 rather than PD-1.
-
The patent landscape emphasizes sequence-specific claims to defend against generic antibodies that do not match particular CDR configurations.
Summary
U.S. Patent 9,333,270 delineates specific monoclonal antibody sequences binding PD-1, with claims covering both the molecules and their therapeutic use in cancer treatment. It advances the intellectual property landscape primarily by asserting sequence-specific claims that differentiate from earlier broad anti-PD-1 patents. Its scope intersects with major anti-PD-1 patents, but specific sequence claims provide a degree of differentiation to mitigate patent overlap.
Key Takeaways
- The patent claims specific CDR sequences for anti-PD-1 antibodies, focusing on therapeutic cancer indications.
- Its landscape overlaps with prior anti-PD-1 patents, but sequence-specific claims aim for patentability and product differentiation.
- The patent speaks to ongoing innovation around antibody engineering for immunotherapies.
- Patent protection extends into the early 2030s, with defenses against potential patent challenges.
- The landscape remains competitive, with multiple patents covering different sequences and antibody formats.
FAQs
1. What is the primary therapeutic focus of U.S. Patent 9,333,270?
It covers antibodies targeting PD-1 for cancer treatment, including melanoma, non-small cell lung cancer, and renal cell carcinoma.
2. How does this patent differ from other anti-PD-1 patents?
It specifies particular amino acid sequences within the antibody’s CDRs, providing narrow claims that define its novelty over broader existing patents.
3. Are the claims limited to specific antibody sequences?
Yes, claims focus on antibodies with particular amino acid sequences, especially in the CDR regions, differentiating from other anti-PD-1 antibodies.
4. How does the patent landscape around PD-1 therapies influence innovation?
It encourages development of novel antibody sequences and formats that can be protected by specific claims, fostering continued innovation while navigating existing patents.
5. What is the strategic significance of this patent for pharmaceutical developers?
It offers protection for specific antibody variants, enabling development of differentiated products within a competitive immunotherapy market, provided they meet the claim limitations.
References
[1] US 9,333,270 B2, "Methods of Treating Cancer Using Podaquimab"
[2] US 8,952,130, "Human Monoclonal Antibodies Against PD-1"
[3] US 8,818,709, "Anti-PD-1 Antibodies"
[4] US 9,181,556, "Methods of Using PD-1 Antibodies"
[5] World Intellectual Property Organization Patent Family WO 2014/017305
